1. The document outlines a 10 step marketing plan for APECS-DM Clinic, a diabetic retinopathy clinic located at the National Kidney and Transplant Institute.
2. The plan's first 5 steps define the primary target market as diabetics aged 50-65 who want to remain functional and avoid blindness, and position APECS against competitors by focusing on holistic diabetic care.
3. The next 5 steps comprise the marketing mix and strategy, including pricing APECS lower than major brands, promoting through education and discounts, and locating at NKTI to leverage its specialized services and dominate the P3 million niche market.
Ocular Disorders-Insight Pharma ReportsDaniel Miller
Available to Insight Pharma Reports is Ocular Disorders: Rising Therapeutics, Technologies, and Devices Report. This report begins with outlining Age-related macular degeneration (both wet and dry) and delving into Anti-VEGF therapies in chapter 2. Further providing substantial weight to this report, several companies were interviewed on their approach to targeting wet and dry AMD, their strategies for seeking alternative therapeutic options, and the hardships they have encountered in their research and product execution.
Ocular Disorders-Insight Pharma ReportsDaniel Miller
Available to Insight Pharma Reports is Ocular Disorders: Rising Therapeutics, Technologies, and Devices Report. This report begins with outlining Age-related macular degeneration (both wet and dry) and delving into Anti-VEGF therapies in chapter 2. Further providing substantial weight to this report, several companies were interviewed on their approach to targeting wet and dry AMD, their strategies for seeking alternative therapeutic options, and the hardships they have encountered in their research and product execution.
Supporting Individuals with Intellectual and Developmental Disability During the First 100 Days of the COVID-19 Outbreak in the U.S.
BrightSpring Health Services Chief Medical Officer Dr. William Mills presents on BrightSpring's ongoing response to COVID-19 and how the organization is mitigating risks for our patients, clients, and team members.
This presentation talks about the Diagnostics & Healthcare industry in India.It includes Marketing Mix,STPD Analysis,SWOT Analysis of some of the top healthcare organizations.
Success Factors and Failure Points in Cardiovascular Product Launches Report ...Best Practices
Biopharmaceutical companies invest large amount of resources to develop and launch new products for cardiovascular therapeutic areas. However, the complexity of a new cardiovascular product launch is compounded by the many pitfalls that are part of the market-entry landscape.
Best Practices ®, LLC undertook this research to showcase current and future risk levels for various pitfalls across critical launch fronts that can derail a new cardiovascular product. Pharmaceutical launch executives can use this study to better understand the potential pitfalls and stumbling blocks that they'll have to navigate as part of a new cardiovascular product entering the market.
Study Overview–- This study explores the executive insights, best practices and lessons learned to avoid common pitfalls while launching a new cardiovascular product into market.
About the Benchmark Class - Forty four executives from 38 leading companies including Abbott, Amgen, Baxter, Bayer, Eisai, GlaxoSmithKline, Merck, Novartis, and Roche participated in this study. Majority of the respondents were at vice president or director level.
Section 1: Study Background -- Reviews the study background, the research approach, methodology, participant demographics, the benchmark class and key findings.
Section 2: Topical chapters -- Outlines valuable insights and findings from the study that includes pitfalls & stumbling blocks, lessons learned and best practices and future changes. Pitfalls chapter reviews current and future risk levels for these cardiovascular launch factors: product shaping, market shaping, physician, patient, payer, internal and regulatory.
Supporting Individuals with Intellectual and Developmental Disability During the First 100 Days of the COVID-19 Outbreak in the U.S.
BrightSpring Health Services Chief Medical Officer Dr. William Mills presents on BrightSpring's ongoing response to COVID-19 and how the organization is mitigating risks for our patients, clients, and team members.
This presentation talks about the Diagnostics & Healthcare industry in India.It includes Marketing Mix,STPD Analysis,SWOT Analysis of some of the top healthcare organizations.
Success Factors and Failure Points in Cardiovascular Product Launches Report ...Best Practices
Biopharmaceutical companies invest large amount of resources to develop and launch new products for cardiovascular therapeutic areas. However, the complexity of a new cardiovascular product launch is compounded by the many pitfalls that are part of the market-entry landscape.
Best Practices ®, LLC undertook this research to showcase current and future risk levels for various pitfalls across critical launch fronts that can derail a new cardiovascular product. Pharmaceutical launch executives can use this study to better understand the potential pitfalls and stumbling blocks that they'll have to navigate as part of a new cardiovascular product entering the market.
Study Overview–- This study explores the executive insights, best practices and lessons learned to avoid common pitfalls while launching a new cardiovascular product into market.
About the Benchmark Class - Forty four executives from 38 leading companies including Abbott, Amgen, Baxter, Bayer, Eisai, GlaxoSmithKline, Merck, Novartis, and Roche participated in this study. Majority of the respondents were at vice president or director level.
Section 1: Study Background -- Reviews the study background, the research approach, methodology, participant demographics, the benchmark class and key findings.
Section 2: Topical chapters -- Outlines valuable insights and findings from the study that includes pitfalls & stumbling blocks, lessons learned and best practices and future changes. Pitfalls chapter reviews current and future risk levels for these cardiovascular launch factors: product shaping, market shaping, physician, patient, payer, internal and regulatory.
1. 1 10 STEP Marketing Plan forAPECS- DM Clinic (Diabetic Retinopathy) Farlah Angela S. Sevilla June 19, 2010
2. 5 Steps for Part 1 (PTM and Positioning) APECS PTM are Diabetics, age 50- 65 Who want to be functional and secured from blindness Can choose SLMC, AEC, AEI, QC eye, EAMC Gap is all other brands focus on eye problem alone. The market size is P300M. APECS niche is P3M.
3. 5 Steps for Part 2(Marketing Mix & Strategy) APECS- DM clinic Is priced lower than leading brands Uses symposia, patient education, discounts and package Is located at the NKTI Uses a niche approach to win
5. 1.APECS- DM clinic’s primary target market (PTM) is.. Demographics (50-65, M/F, class ABC) Lifestyle (active or retirees, with pre-existing DM or impaired glucose, smoking history, poor diet and physical inactivity) Behavior (monthly/quarterly consult, 500/consult, DM control & complications)
6. I need to become functional again I want to be less of a burden I want to be protected from blindness
7. 2. My PTM’s NWE Diabetics need… To belong (social), functional again, Self actualization Diabetics choose APECS over other DM clinics because of …. Competent doctors and staff, within a referral center (NKTI), nice clinic with complete equipments, and reasonable price Diabetics expect this when they go to APECS- DM clinic… Informed and empowered with more knowledge about their disease, and security from blindness
8. 3a. APECS- DM clinic has many formidable competitors Direct: QC Eye, East Avenue Medical Center (EAMC), St Lukes Medical Center (SLMC), American Eye Center (AEC), Asian Eye Institute (AEI) Indirect: other tertiary hospitals, retina specialists, general ophthalmologists, optometrists, EENT specialists Variables: Competence, Price, Rapport to patients, availability of equipments and services, clinic ambience, referrals to other specialties (ophtha and non- ophtha)
9. APECS is #1 in niche: middle priced and referral to other MD specialists Price vs. ease of referral SLMC AEI AEC APECS QC eye EAMC
10. APECSunique positioning is shown in this competitive map Positioning vs. Service Provider Many competitors focus on eye problem alone and do not place much emphasis on holistic care of diabetic patients .
11. 4. APECS positions strongly in a niche market opportunity APECS is the only DM clinic that has competent doctors, specialists, staff With state of the art equipments (specifically for DM- retina patients) With subspecialty clinics and services (dialysis and kidney transplant centers, nutrition clinic, endocrine No brand has a similar position. Others focus on eye problem alone.
12. 5a. Based on competitor data, DM market is P287 million EAMC estimates : Patients= 1920 x P200= P384,000 Laser= 720 x P2000= P1.4M Surgery= 240 x P16500= P3.96M Estimated market share= 2% P5.7M/0.02= P287M
13. 5b. Based on APECS data, where market share is 1%, total market size is P300 million APECS data: sales is P3 M APECS claims market share of 1% Then total market size is P3 million/0.01 = P 300M
14. 5c. Consumer data indicates a total size of P 318M Ophtha DM consult alone: (based on prevalence of DM) 429 thousand DM Filipinos (50-65) consult on an average of 1x/ year= 6.5m x P500= 214.5 M (based on prevalence of DR) 122 thousand DM x P500= 61M
15. 5c. Consumer data indicates a total size of P 318M On laser and surgery of DM patients: LASER:(based on prevalence of DR severity) 12.2 thousand DM Filipinos x P2,000/eye (PHIC-RVU) = 24M SURGERY: 1098 DM Filipinos x P16,500 (PHIC-RVU)= 18M
16. 5. Concluded that DM clinic market is P300 million Competitor data= P287M Company data = P 300M Usage data = P 318M
17. 17 The Marketing Mix Strategy Part 2: Steps 6 to 10
25. 6b. Product Description Asia Pacific Eye Care Specialists (APECS) is an eye clinic located at the Dialysis Center and Doctors Clinic of the National Kidney and Transplant Institute. Services offered: Vision screening and correction, Retina Diagnostics and Treatment, Glaucoma Screening and Diagnostics, Pedia Vision Screening and diagnostics, Ocular infections and inflammation, and Ophthalmic surgeries
26. 6b. Product Description APECS has 8 competent, experienced Ophthalmologists with different sub-specialties: Cataract and Refractive Pediatric Ophthalmologist Medical and Surgical Vitreoretina specialist Ocular inflammation and uveitis External Disease and Cornea
27. 7. Prices- APECS is priced at par or lower than competitors APECS consult (regardless of specialty)= P500 APECS retina surgery= P 25- 40k APECS laser treatment= P12- 15k APECS is priced at par with QC eye and 40% higher than EAMC with aim of maximizing profits in its niche. APECS is priced 25- 40% lower than AEC, AEI.
36. 9. APECS is located at the NKTI Doctors Clinic
37. 10. APECS- DM Clinic is a niche leader APECS’ main strategy is to dominate the niche market of 50- 65 year old diabetics who need to still be functional and protected from blindness due to diabetes. It benefits from its location, within a specialized tertiary hospital.
38. 38 SUMMARY 10 STEP Marketing Plan for APECS- DM Clinic (Diabetic Retinopathy)
39. 5 Steps for Part 1 (PTM and Positioning) APECS PTM are Diabetics, age 50- 65 Who want to be functional and secured from blindness Can choose SLMC, AEC, QC eye, EAMC Gap is all other brands focus on eye problem alone. The market size is P300M. APECS niche is P3M.
40. 5 Steps for Part 2(Marketing Mix & Strategy) APECS- DM clinic Is priced lower than leading brands Uses symposia, patient education, discounts and package Is located at the NKTI Uses a niche approach to win
41. 41 10 STEP Marketing Plan forAPECS- DM Clinic (Diabetic Retinopathy) Farlah Angela S. Sevilla June 19, 2010